Performance status of patients is the major prognostic factor at all stages of pancreatic cancer
Background The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer. Materials and method The data of 335 patients with histologically confirmed diagnosis of pancr...
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2013-10, Vol.18 (5), p.839-846 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 846 |
|---|---|
| container_issue | 5 |
| container_start_page | 839 |
| container_title | International journal of clinical oncology |
| container_volume | 18 |
| creator | Tas, Faruk Sen, Fatma Odabas, Hatice Kılıc, Leyla Keskın, Serkan Yıldız, Ibrahım |
| description | Background
The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer.
Materials and method
The data of 335 patients with histologically confirmed diagnosis of pancreatic cancer who were treated and followed up between 2000 and 2010 were recorded from medical charts.
Results
The median age of the patients was 59 years (range 25–88 years) and 226 (67.5 %) were male. The study group comprised localized disease (18 %), locally advanced disease (36 %) and metastatic disease (46 %). The median survival of all patients was 280 days and the 4-year survival rate was 5 %. Univariate analysis indicated that initial poor performance status of patients (PS 2–4) was significantly associated with shorter survival in localized (
p
= 0.015), locally advanced (
p
= 0.01), metastatic stage (
p
|
| doi_str_mv | 10.1007/s10147-012-0474-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1443418870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1443418870</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-f6a8f3b2d8e3e49ded5d43ab0199c64dcaeac7f4c0212d1e40b0d74bbb8386073</originalsourceid><addsrcrecordid>eNp1kE1LxDAURYMozjj6A9xIwI2b6kuaSdqliF8woAtdxzR9HTv0Y0zShf_elI4igquE5Nz7HoeQUwaXDEBdeQZMqAQYT0AokeR7ZM5EqhKlFN-P91SwJJd8OSNH3m8AmJJLfkhmnOe5ZILNydszuqp3reksUh9MGDztK7o1ocYueFp7Gt6RtmbTO7p1_brrfagtrYwN8cUEappmDK5xF-ysQzMidux0x-SgMo3Hk925IK93ty83D8nq6f7x5nqVWCF5SCppsioteJlhiiIvsVyWIjUFsDy3UpTWoLGqEhY44yVDAQWUShRFkaWZBJUuyMXUG5f8GNAH3dbeYtOYDvvBayZEtJFlCiJ6_gfd9IPr4nYjxSXAMpORYhNlXe-9w0pvXd0a96kZ6FG_nvTrqF-P-nUeM2e75qFosfxJfPuOAJ8AH7-6Nbpfo_9t_QI3gpB_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1442600586</pqid></control><display><type>article</type><title>Performance status of patients is the major prognostic factor at all stages of pancreatic cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Tas, Faruk ; Sen, Fatma ; Odabas, Hatice ; Kılıc, Leyla ; Keskın, Serkan ; Yıldız, Ibrahım</creator><creatorcontrib>Tas, Faruk ; Sen, Fatma ; Odabas, Hatice ; Kılıc, Leyla ; Keskın, Serkan ; Yıldız, Ibrahım</creatorcontrib><description>Background
The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer.
Materials and method
The data of 335 patients with histologically confirmed diagnosis of pancreatic cancer who were treated and followed up between 2000 and 2010 were recorded from medical charts.
Results
The median age of the patients was 59 years (range 25–88 years) and 226 (67.5 %) were male. The study group comprised localized disease (18 %), locally advanced disease (36 %) and metastatic disease (46 %). The median survival of all patients was 280 days and the 4-year survival rate was 5 %. Univariate analysis indicated that initial poor performance status of patients (PS 2–4) was significantly associated with shorter survival in localized (
p
= 0.015), locally advanced (
p
= 0.01), metastatic stage (
p
< 0.001) and in the whole group (
p
< 0.001). Multivariate analyses also showed the same findings except in local disease (
p
= 0.04 for locally advanced disease,
p
= 0.002 for metastatic stage, and
p
< 0.001 for all stages). In patients with poor performance status, severe weight loss (>10 %) (
p
= 0.007), large tumor diameter (>3 cm) (
p
= 0.046), and especially metastatic disease (
p
< 0.001) were associated with significantly shorter overall survival.
Conclusions
The performance status of a patient is the major prognostic factor predicting overall survival for all stages of pancreatic cancer. Severe weight loss, large tumor, and metastatic disease were found to be unfavorable prognostic factors in patients with poor performance status.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-012-0474-9</identifier><identifier>PMID: 22996141</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Cancer Research ; Disease-Free Survival ; Female ; Humans ; Male ; Medical diagnosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate Analysis ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Neoplasm Staging ; Oncology ; Original Article ; Pancreatic cancer ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - therapy ; Prognosis ; Surgical Oncology ; Treatment Outcome ; Tumors</subject><ispartof>International journal of clinical oncology, 2013-10, Vol.18 (5), p.839-846</ispartof><rights>Japan Society of Clinical Oncology 2012</rights><rights>Japan Society of Clinical Oncology 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-f6a8f3b2d8e3e49ded5d43ab0199c64dcaeac7f4c0212d1e40b0d74bbb8386073</citedby><cites>FETCH-LOGICAL-c462t-f6a8f3b2d8e3e49ded5d43ab0199c64dcaeac7f4c0212d1e40b0d74bbb8386073</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-012-0474-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-012-0474-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22996141$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tas, Faruk</creatorcontrib><creatorcontrib>Sen, Fatma</creatorcontrib><creatorcontrib>Odabas, Hatice</creatorcontrib><creatorcontrib>Kılıc, Leyla</creatorcontrib><creatorcontrib>Keskın, Serkan</creatorcontrib><creatorcontrib>Yıldız, Ibrahım</creatorcontrib><title>Performance status of patients is the major prognostic factor at all stages of pancreatic cancer</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer.
Materials and method
The data of 335 patients with histologically confirmed diagnosis of pancreatic cancer who were treated and followed up between 2000 and 2010 were recorded from medical charts.
Results
The median age of the patients was 59 years (range 25–88 years) and 226 (67.5 %) were male. The study group comprised localized disease (18 %), locally advanced disease (36 %) and metastatic disease (46 %). The median survival of all patients was 280 days and the 4-year survival rate was 5 %. Univariate analysis indicated that initial poor performance status of patients (PS 2–4) was significantly associated with shorter survival in localized (
p
= 0.015), locally advanced (
p
= 0.01), metastatic stage (
p
< 0.001) and in the whole group (
p
< 0.001). Multivariate analyses also showed the same findings except in local disease (
p
= 0.04 for locally advanced disease,
p
= 0.002 for metastatic stage, and
p
< 0.001 for all stages). In patients with poor performance status, severe weight loss (>10 %) (
p
= 0.007), large tumor diameter (>3 cm) (
p
= 0.046), and especially metastatic disease (
p
< 0.001) were associated with significantly shorter overall survival.
Conclusions
The performance status of a patient is the major prognostic factor predicting overall survival for all stages of pancreatic cancer. Severe weight loss, large tumor, and metastatic disease were found to be unfavorable prognostic factors in patients with poor performance status.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Cancer Research</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Prognosis</subject><subject>Surgical Oncology</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1LxDAURYMozjj6A9xIwI2b6kuaSdqliF8woAtdxzR9HTv0Y0zShf_elI4igquE5Nz7HoeQUwaXDEBdeQZMqAQYT0AokeR7ZM5EqhKlFN-P91SwJJd8OSNH3m8AmJJLfkhmnOe5ZILNydszuqp3reksUh9MGDztK7o1ocYueFp7Gt6RtmbTO7p1_brrfagtrYwN8cUEappmDK5xF-ysQzMidux0x-SgMo3Hk925IK93ty83D8nq6f7x5nqVWCF5SCppsioteJlhiiIvsVyWIjUFsDy3UpTWoLGqEhY44yVDAQWUShRFkaWZBJUuyMXUG5f8GNAH3dbeYtOYDvvBayZEtJFlCiJ6_gfd9IPr4nYjxSXAMpORYhNlXe-9w0pvXd0a96kZ6FG_nvTrqF-P-nUeM2e75qFosfxJfPuOAJ8AH7-6Nbpfo_9t_QI3gpB_</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Tas, Faruk</creator><creator>Sen, Fatma</creator><creator>Odabas, Hatice</creator><creator>Kılıc, Leyla</creator><creator>Keskın, Serkan</creator><creator>Yıldız, Ibrahım</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20131001</creationdate><title>Performance status of patients is the major prognostic factor at all stages of pancreatic cancer</title><author>Tas, Faruk ; Sen, Fatma ; Odabas, Hatice ; Kılıc, Leyla ; Keskın, Serkan ; Yıldız, Ibrahım</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-f6a8f3b2d8e3e49ded5d43ab0199c64dcaeac7f4c0212d1e40b0d74bbb8386073</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Cancer Research</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Prognosis</topic><topic>Surgical Oncology</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tas, Faruk</creatorcontrib><creatorcontrib>Sen, Fatma</creatorcontrib><creatorcontrib>Odabas, Hatice</creatorcontrib><creatorcontrib>Kılıc, Leyla</creatorcontrib><creatorcontrib>Keskın, Serkan</creatorcontrib><creatorcontrib>Yıldız, Ibrahım</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tas, Faruk</au><au>Sen, Fatma</au><au>Odabas, Hatice</au><au>Kılıc, Leyla</au><au>Keskın, Serkan</au><au>Yıldız, Ibrahım</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Performance status of patients is the major prognostic factor at all stages of pancreatic cancer</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>18</volume><issue>5</issue><spage>839</spage><epage>846</epage><pages>839-846</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
The aim of this study was to identify and evaluate the clinicopathologic factors and to elucidate the clinical importance of performance status on the outcome of patients with pancreatic cancer.
Materials and method
The data of 335 patients with histologically confirmed diagnosis of pancreatic cancer who were treated and followed up between 2000 and 2010 were recorded from medical charts.
Results
The median age of the patients was 59 years (range 25–88 years) and 226 (67.5 %) were male. The study group comprised localized disease (18 %), locally advanced disease (36 %) and metastatic disease (46 %). The median survival of all patients was 280 days and the 4-year survival rate was 5 %. Univariate analysis indicated that initial poor performance status of patients (PS 2–4) was significantly associated with shorter survival in localized (
p
= 0.015), locally advanced (
p
= 0.01), metastatic stage (
p
< 0.001) and in the whole group (
p
< 0.001). Multivariate analyses also showed the same findings except in local disease (
p
= 0.04 for locally advanced disease,
p
= 0.002 for metastatic stage, and
p
< 0.001 for all stages). In patients with poor performance status, severe weight loss (>10 %) (
p
= 0.007), large tumor diameter (>3 cm) (
p
= 0.046), and especially metastatic disease (
p
< 0.001) were associated with significantly shorter overall survival.
Conclusions
The performance status of a patient is the major prognostic factor predicting overall survival for all stages of pancreatic cancer. Severe weight loss, large tumor, and metastatic disease were found to be unfavorable prognostic factors in patients with poor performance status.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>22996141</pmid><doi>10.1007/s10147-012-0474-9</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2013-10, Vol.18 (5), p.839-846 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1443418870 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Aged, 80 and over Cancer Research Disease-Free Survival Female Humans Male Medical diagnosis Medicine Medicine & Public Health Middle Aged Multivariate Analysis Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Neoplasm Staging Oncology Original Article Pancreatic cancer Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy Prognosis Surgical Oncology Treatment Outcome Tumors |
| title | Performance status of patients is the major prognostic factor at all stages of pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T04%3A16%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Performance%20status%20of%20patients%20is%20the%20major%20prognostic%20factor%20at%20all%20stages%20of%20pancreatic%20cancer&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Tas,%20Faruk&rft.date=2013-10-01&rft.volume=18&rft.issue=5&rft.spage=839&rft.epage=846&rft.pages=839-846&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-012-0474-9&rft_dat=%3Cproquest_cross%3E1443418870%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1442600586&rft_id=info:pmid/22996141&rfr_iscdi=true |